Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: A randomised controlled trial

Lancet Oncology

Volumn 7, Issue 1, 2006, Pages 43-51

  Di Stasi, Savino M ^a,i   Giannantoni, Antonella ^b   Giurioli, Arcangelo ^c   Valenti, Marco ^d   Zampa, Germano ^e   Storti, Luigi ^f   Attisani, Francesco ^a   De Carolis, Andrea ^a   Capelli, Giovanni ^g   Vespasiani, Giuseppe ^a   Stephen, Robert L ^h  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c A Perrino Hospital   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e S Giacomo Hospital   (Italy)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g UNIVERSITY OF CASSINO AND SOUTHERN LAZIO   (Italy)

^h Physion Laboratories   (Italy)

ⁱ NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; EPIRUBICIN; GEMCITABINE; INTERFERON; MITOMYCIN;

ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; BLADDER CONTRACTION; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DYSURIA; ELECTRIC CURRENT; EPIDIDYMITIS; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEMATURIA; HUMAN; HUMAN TISSUE; LIVER TOXICITY; LUNG INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALAISE; MALE; PRIORITY JOURNAL; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEPSIS; SIDE EFFECT; STATISTICAL ANALYSIS; TRANSURETHRAL RESECTION; URETER OBSTRUCTION;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ELECTRIC STIMULATION THERAPY; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MITOMYCIN; MUCOUS MEMBRANE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 29744470225     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70472-1     Document Type: Article

References (31)

1. JA Smith RF Labasky ATK Cockett et al Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis) J Urol 162 1999 1697-1701
2. RJ Sylvester APM van der Meijden DL Lamm Intravesical bacillus Calmette-Guèrin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964-1970
3. JL Au RA Badalament MG Wientjes et al Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial J Natl Cancer Inst 93 2001 597-604
4. MG Wientjes RA Badalament JL Au Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C treatment for superficial bladder cancer Cancer Chemother Pharmacol 32 1993 255-262
5. SM Di Stasi G Vespasiani A Giannantoni et al Electromotive delivery of mitomycinc C into human bladder wall Cancer Res 57 1997 875-880
6. M Brausi B Campo G Pizzocaro et al Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: A comparative phase II study Urology 51 1998 506-509
7. SM Di Stasi A Giannantoni R Massoud et al Electromotive versus passive diffusion of mitomycin C into human bladder wall: Concentration-depth profiles studies Cancer Res 59 1999 4912-4918
8. SM Di Stasi A Giannantoni RL Stephen et al Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: A prospective randomized study J Urol 170 2003 777-782
9. E Rintala K Jauhiainen P Rajala et al Alternating mitomycin C and bacillus Calmette-Guèrin instillation treatment for carcinoma in situ of the bladder J Urol 154 1995 2050-2053
10. E Rintala K Jauhiainen E Kaasinen et al for the Finnbladder Group Alternating mitomycin C and bacillus Calmette-Guèrin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer J Urol 156 1996 56-59
11. E Kaasinen E Rintala AK Pere et al Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma J Urol 164 2000 47-52
12. E Kaasinen E Rintala P Hellstrom et al Factors explaining recurrence in patients undergoing chemoimmunotreatment regimens for frequently recurring superficial bladder carcinoma Eur Urol 42 2002 167-174
13. E Kaasinen H Wijkstrom PU Malmstrom et al Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: A nordic study Eur Urol 43 2003 637-645
14. JA Witjes CTM Caris NA Mungan et al Results of a randomized phase III trial of sequential intravesical treatment with mitomycin C and bacillus Calmette-Guèrin versus mitomycin C alone in patients with superficial bladder cancer J Urol 160 1998 1668-1671
15. APM Van der Meijden RR Hall MP Macaluso A Pawinsky et al Marker tumour response to the sequential combination of intravesical treatment with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours Eur Urol 29 1996 199-203
16. LH Sobin CH Wittekind UICC (International Union Against Cancer) TNM classification of malignant tumours 5th edn. 1997 Wiley Liss New York 107-190
17. FK Mostofi LH Sobin H Torloniu Histological typing of urinary bladder tumours: International Classification of Tumours, No 10 1973 World Health Organization Geneva
18. DL Lamm BA Blumenstein ED Crawford et al A randomized trial of intravesical doxorubicin and immunotreatment with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder N Engl J Med 325 1991 1205-1209
19. MD Melekos HS Chionis GS Paranychianakis HH Dauaher et al Intravesical 4′-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guerin. A controlled prospective study on the prophylaxis of superficial bladder cancer Cancer 72 1993 1749-1755
20. JC Kim GD Steinberg The limits of bacillus Calmette-Guèrin for carcinoma in situ of the bladder J Urol 165 2001 745-756
21. AB Alexandroff AM Jackson MA O'Donnell K James BCG immunotreatment of bladder cancer: 20 years on Lancet 353 1999 1689-1694
22. Y Gan Y Mo JE Kalns et al Expression of DT-Diaphorase and Cytochrome P450 Reductase correlates with mitomycin C activity in human bladder tumours Clin Cancer Res 7 2001 1313-1319
23. F Chen G Zhang Y Iwamoto WA See BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as consequence of integrin cross-linking BMC Urol 5 2005 8
24. J Den Hartigh JG Mc Vie WJ van Oort HM Pinedo Pharmacokinetics of mitomycin C in humans Cancer Res 43 1983 5017-5021
25. LT Balemans PD Vegt PA Steerenberg et al Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guèrin on the immune response in the guinea pig bladder Urol Res 22 1994 239-245
26. SM Di Stasi A Giannantoni RL Stephen et al Percutaneous sequential bacillus Calmette-Guerin and mitomycin C for panurothelial carcinomatosis Can J Urol 12 2005 2895-2898
27. HW Herr Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin treatment J Urol 174 2005 2134-2137
28. MS Soloway M Sofer A Vaidya Contemporary management of stage T1 transitional cell carcinoma of the bladder J Urol 167 2002 1573-1583
29. MO Grimm R Ackermann Transurethral resection of superficial bladder cancer: Technically safe, oncologically anything but perfect J Urol 174 2005 2086-2087
30. E Solsona I Iborra JV Ricos et al Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: Short and long-term follow up J Urol 161 1999 1120-1123
31. JA Martinez-Pineiro L Martinez-Pineiro E Solsona et al Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumours than the standard dose? Results of a prospective randomized trial J Urol 174 2005 1242-1247